Literature DB >> 17896836

Selective targeting of cancer stem cells: a new concept in cancer therapeutics.

Hasan Korkaya1, Max S Wicha.   

Abstract

Although the concept of 'cancer stem cell' was first proposed more then a century ago, it has attracted a great deal of attention recently due to advances in stem cell biology, leading to the identification of these cells in a wide variety of human cancers. There is accumulating evidence that the resistance of cancer stem cells to many conventional therapies may account for the inability of these therapies to cure most metastatic cancers. The recent identification of stem cell markers and advances in stem cell biology have facilitated research in multiple aspects of cancer stem cell behavior. Stem cell subcomponents have now been identified in a number of human malignancies, including hematologic malignancies and tumors of the breast, prostate, brain, pancreas, head and neck, and colon. Furthermore, pathways that regulate self-renewal and cell fate in these systems are beginning to be elucidated. In addition to pathways such as Wnt, Notch and Hedgehog, known to regulate self-renewal of normal stem cells, tumor suppressor genes such as PTEN (phosphatase and tensin homolog on chromosome 10) and TP53 (tumor protein p53) have also been implicated in the regulation of cancer stem cell self-renewal. In cancer stem cells, these pathways are believed to be deregulated, leading to uncontrolled self-renewal of cancer stem cells which generate tumors that are resistant to conventional therapies. Current cancer therapeutics based on tumor regression may target and kill differentiated tumor cells, which compose the bulk of the tumor, while sparing the rare cancer stem cell population. The cancer stem cell model suggests that the design of new cancer therapeutics may require the targeting and elimination of cancer stem cells. Therefore, it is imperative to design new strategies based upon a better understanding of the signaling pathways that control aspects of self-renewal and survival in cancer stem cells in order to identify novel therapeutic targets in these cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17896836     DOI: 10.2165/00063030-200721050-00002

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  56 in total

Review 1.  Targeting Notch to target cancer stem cells.

Authors:  Antonio Pannuti; Kimberly Foreman; Paola Rizzo; Clodia Osipo; Todd Golde; Barbara Osborne; Lucio Miele
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

Review 2.  Targeting breast cancer stem cells.

Authors:  Suling Liu; Max S Wicha
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

3.  Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells.

Authors:  Michael W Sim; Patrick T Grogan; Chitra Subramanian; Carol R Bradford; Thomas E Carey; M Laird Forrest; Mark E Prince; Mark S Cohen
Journal:  Laryngoscope       Date:  2015-12-21       Impact factor: 3.325

4.  Biophysical Regulation of Cancer Stem/Initiating Cells: Implications for Disease Mechanisms and Translation.

Authors:  Joseph Chen; Sanjay Kumar
Journal:  Curr Opin Biomed Eng       Date:  2017-05-19

5.  HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.

Authors:  H Korkaya; A Paulson; F Iovino; M S Wicha
Journal:  Oncogene       Date:  2008-06-30       Impact factor: 9.867

6.  FL118, a novel survivin inhibitor, wins the battle against drug-resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties.

Authors:  Jin Wang; Zhantao Liu; Dandan Zhang; Ranran Liu; Qian Lin; Jia Liu; Zhihong Yang; Qingxia Ma; Dantong Sun; Xin Zhou; Guohui Jiang
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

7.  Inhibition of C-terminal binding protein attenuates transcription factor 4 signaling to selectively target colon cancer stem cells.

Authors:  Jagrut Patel; Somesh Baranwal; Ian M Love; Nirmita J Patel; Steven R Grossman; Bhaumik B Patel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.

Authors:  Christophe Ginestier; Suling Liu; Mark E Diebel; Hasan Korkaya; Ming Luo; Marty Brown; Julien Wicinski; Olivier Cabaud; Emmanuelle Charafe-Jauffret; Daniel Birnbaum; Jun-Lin Guan; Gabriela Dontu; Max S Wicha
Journal:  J Clin Invest       Date:  2010-01-04       Impact factor: 14.808

9.  CTIP2 expression in human head and neck squamous cell carcinoma is linked to poorly differentiated tumor status.

Authors:  Gitali Ganguli-Indra; Christine Wasylyk; Xiaobo Liang; Regine Millon; Mark Leid; Bohdan Wasylyk; Joseph Abecassis; Arup K Indra; Arup Indra
Journal:  PLoS One       Date:  2009-04-28       Impact factor: 3.240

10.  MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells.

Authors:  Qing Ji; Xinbao Hao; Min Zhang; Wenhua Tang; Meng Yang; Ling Li; Debing Xiang; Jeffrey T Desano; Guido T Bommer; Daiming Fan; Eric R Fearon; Theodore S Lawrence; Liang Xu
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.